Hikma Pharmaceuticals PLC (Hikma), the fast growing multinational pharmaceutical group with sales covering 50 countries across Europe, the Middle East and North Africa (MENA and the US, reported a 19.9% increase in revenues to $638.3 million for the six months ended 30 June 2013.
The Group delivered a strong performance in the first half of 2013, with a 19.9% increase in revenue to $638.3 million. This reflects strong performances across its businesses. The Group is expected to deliver full year revenue growth of around 20%.
Through its ongoing commitment to society’s health and community needs with the sole aim of providing affordable high quality medication to patients, Hikma continued new product introductions across all countries and markets; and launched 63 products and received 65 product approvals.
Stronger sales are expected in the MENA region in the second half and the Branded business continues to remain on track for around 11% full year revenue growth in constant currency, alongside driving operational efficiencies in local manufacturing facilities.
A favourable performance of the global Injectables business will be sustained in the second half of 2013, driven by strong performances in the US and Europe. As for the Generics business, the antibiotic Doxycycline sales have been significant, leading to an increase in the Generics revenue guidance for the full year.
“I am very pleased that the Group has made an excellent start to this year and that all of our businesses are performing well,” Mazen Darwazah, Hikma’s Executive Vice-Chairman and Chief Executive Officer of MENA, said.
“In the MENA region, we continue to focus on offering products that reflect the needs of the patient population in all our markets. Hikma has been continuously contributing to its communities and investing in its people – Our unwavering commitment to our local markets has been reinforced through our dedication to Corporate Social Responsibility and promotion of integral practices that support our people and societies. Our global Injectables business continues to deliver very strong growth. In particular, we are benefitting from strong demand for our products in the US and new product launches.”
“I expect the outlook to be positive for the second half of this year with great growth opportunities for the entire Group.”